Assessment of High Intensity Focused Ultrasound for the Treatment of Prostate Cancer

References

• Han M., Partin A. W., Pound e. R., Epstein J. I., Walsh P. C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am, 2001, 28 (3): 555–565.
   Google Scholar
• Hull G. W., Rabbani F., Abbas F., Wheeler T. M., Kattan M. W., Scardino P. T. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol, 2002, 167 (2 Pt 1): 528–534.
   Google Scholar
• Nilsson S., Norlen B. J., Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol, 2004, 43 (4): 316–381.
   Google Scholar
• Ataman F., Zurlo A., Artignan X. et al. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer, 2004, 40 (11): 1674–1681.
   Google Scholar
• Robinson J. W., Moritz S., Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys, 2002, 54 (4): 1063–1068.
   Google Scholar
• Stanford J. L., Feng Z., Hamilton A. S. et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA, 2000, 283 (3): 354–360.
   Google Scholar
• Murat F.-J., Poissonnier L., Pasticier G., Gelet A. High-intensity focused ultrasound (HIFU) for prostate cancer. Cancer Control,2007, 14 (3): 244–249.
   Google Scholar
• Chaussy C., Thuroff S., Bergsdorf T. Das Lokalrezidiv des Prostatakarzinoms nach kurativer Therapie. Therapieoption HIFU (Ablatherm). Der Urologe, 2006, 45 (10): 1271–1275.
   Google Scholar
• Beerlage H. P., Thuroff S., Debruyne F. M., Chaussy C., de la Rosette J. J. Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology, 1999, 54 (2): 273–277.
   Google Scholar
• Obyn C., Mambourg F. Rapid assessment van enkele nieuwe behandelingen voor prostaatkanker en goedaardige prostaat-hypertrofie: High-Intensity Focused Ultrasound (HIFU) voor prostaatkanker. Photoselective Vaporization of the Prostate (PVP) en holmium laser voor goedaardige prostaathypertrofie. Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE),
   Google Scholar
• Merglen A., Schmidlin F., Fioretta G. et al. Short-and long-term mortality with localized prostate cancer. Arch Intern Med, 2007, 167 (18): 1944–1950.
   Google Scholar
• NICE. Interventional procedure overview of high intensity focused ultrasound for prostate cancer, 2004.
   Google Scholar
• Blana A. et al. First Analysis of the Long-Term Results with Transrectal HIFU in Patients with Localised Prostate Cancer. Eur Urol, 2007.
   Google Scholar
• Lee H. M., Hong J. H., Choi H. Y. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis, 2006, 9 (4): 439–443.
   Google Scholar
• Poissonnier L., Chapelon J.-Y., Rouviere O. et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol, 2007, 51 (2): 381–387.
   Google Scholar
• Gelet A., Chapelon J. Y., Poissonnier L. et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology, 2004, 63 (4): 625–629.
   Google Scholar
• Murat. Mid-term Results Demonstrate Salvage High-Intensity Focused Ultrasound (HIFU) as an Effective and Acceptably Morbid Salvage Treatment Option for Locally Radiorecurrent Prostate Cancer. Eur Urol, 2008.
   Google Scholar
• Mambourg F., Van den Bruel A., Devriese S. et al. Health Technology Assessment prostate-specific-antigen (PSA) voor prostaatkankerscreening. Brussels: Belgian Health Care Knowledge Centre (KCE), 2006.
   Google Scholar
• European Association Of Urology. Guidelines on prostate cancer. European association of Urology, 2008.
   Google Scholar
• NICE. Prostate cancer: diagnosis and treatment Developed for NICE by the National Collaborating Centre for Cancer, 2008.
   Google Scholar
• Uchida T., Ohkusa H., Yamashita H. et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol, 2006, 13 (3): 228–33.
   Google Scholar
• Comité d’Evaluation et de Diffusion des Innovations Technologiques. High intensity focused ultrasound (HIFU) for the treatment of localised prostate cancer (Ablatherm (R) system)-systematic review, expert panel. Report: Comite d’Evaluation et de Diffusion des Innovations Technologiques (CEDIT), 2004.
   Google Scholar
• Thuroff S., Chaussy C., Vallancien G. et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol, 2003, 17 (8): 673–677.
   Google Scholar
• Chaussy C., Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep, 2003, 4 (3): 248–252.
   Google Scholar
• Blana A., Rogenhofer S., Ganzer R., Wild P. J., Wieland W. F., Walter B. Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol, 2006, 24 (5): 585–590.
   Google Scholar
• Chaussy C. G., Thuroff S. High-intensive focused ultrasound in localized prostate cancer. J Endourol, 2000, 14 (3): 293–299.
   Google Scholar
• Chaussy C., Thuroff S. High-intensity focused ultrasound in prostate cancer: results after 3 years. Mol Urol, 2000, 4 (3): 179–182.
   Google Scholar
• Thuroff S., Chaussy e. High-intensity focused ultrasound: complications and adverse events. Mol Urol, 2000, 4 (3): 183–187, discussion 89.
   Google Scholar
• Chaussy C., Thuroff S. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol, 2001, 15 (4): 437–440, discussion 47–48.
   Google Scholar
• Roach M. 3rd, Hanks G., Thames H. Jr. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys, 2006, 65 (4): 965–974.
   Google Scholar
• Gelet A., Chapelon J. Y., Bouvier R. et al. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol, 1996, 29 (2): 174–183.
   Google Scholar
• Gelet A., Chapelon J. Y., Bouvier R., Pangaud C., Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol, 1999, 161 (1): 156–162.
   Google Scholar
• Gelet A., Chapelon J. Y., Bouvier R. et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol, 2000, 14 (6): 519–528.
   Google Scholar
• Poissonnier L., Gelet A., Chapelon J.-Y. et al. [Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or + 10 ng/ml]. Prog Urol, 2003, 13 (1): 60–72.
   Google Scholar
• Gelet A., Poissonnier L., Chapelon J.-Y. et al. Traitement par ultrasons focalisés du cancer localisé de la prostate: Résultats carcinologiques et pronostic sexuel. Andrologie, 2003, 13 (3): 242–251.
   Google Scholar
• Blana A., Walter B., Rogenhofer S., Wieland W. F. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology, 2004, 63 (2): 297–300.
   Google Scholar